US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Lakewood-Amedex Biotherapeutics (Direct Listing)

0.8498

-0.0172-1.98%

Post-market: 0.86990.0201+2.37%19:54 EDT

Volume:8.50M

Turnover:7.91M

Market Cap:2.01M

PE:-0.27

High:0.9000

Open:0.7800

Low:0.7610

Close:0.8670

52wk High:98.20

52wk Low:0.7610

Shares:2.37M

Float Shares:1.39M

Volume Ratio:37.88

T/O Rate:612.34%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.1006

EPS(LYR):-8.3987

ROE:-402.84%

ROA:-139.40%

PB:0.46

PE(LYR):-0.10

Loading ...

Overview Company News Filings

Lakewood-Amedex Says Lead Bisphosphocin Candidate Nu-3 Posts Phase 2a Diabetic Foot Ulcer Trial Data in Q1 2027

Lakewood-Amedex Biotherapeutics - Bisphosphocin Nu-3 Phase 2a Trial Topline Data Expected Q1 2027

THOMSON REUTERS

Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds

THOMSON REUTERS

Lakewood-Amedex CEO Presents Nu-3 Preclinical Poster at IDWeek

Lakewood-Amedex Biotherapeutics Holds Annual Shareholder Meeting

Why Is Penny Stock Lakewood-Amedex Biotherapeutics (LABT) Up 20% Today?

Lakewood-Amedex Biotherapeutics reports positive MIC data from Nu-3 study

Lakewood-Amedex Reports Positive MIC Data for Nu-3 Against Infected Diabetic Foot Ulcer Isolates

Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers

THOMSON REUTERS

Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers

THOMSON REUTERS

Lakewood-Amedex Biotherapeutics Lists on NASDAQ Capital Market Under LABT Ticker

Lakewood-Amedex Biotherapeutics - Prospectus Filed for Resale of up to 4,512,400 Shares of Common Stock by Certain Selling Stockholder - SEC Filing

THOMSON REUTERS

Lakewood-Amedex Biotherapeutics Announces Irb Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers

THOMSON REUTERS

Lakewood-Amedex Biotherapeutics CEO Presents at H.C. Wainwright Global Investment Conference

Lakewood-Amedex Q2 FY26 Net Loss Widens to $3.77 Million; R&D Expense More than Doubled to $503,020

Lakewood-Amedex Biotherapeutics Announces Annual Shareholder Meeting

Lakewood-Amedex Biotherapeutics Announces Annual Shareholder Meeting

Lakewood-amedex Biotherapeutics Flags New Press Release Available on Nu-3 Resistance Data

Lakewood-Amedex announces preclinical data from Phase 2a clinical trial

Lakewood-amedex Biotherapeutics Reports Release Available on Nu-3 Gel Preclinical Safety Data

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/LABT/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LABT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABT\",,,,,undefined,":{"symbol":"LABT","market":"US","secType":"STK","nameCN":"Lakewood-Amedex Biotherapeutics (Direct Listing)","latestPrice":0.8498,"timestamp":1791403200000,"preClose":0.867,"halted":0,"volume":8498672,"hourTrading":{"tag":"盘后","latestPrice":0.8699,"preClose":0.8498,"latestTime":"19:54 EDT","volume":41373,"amount":35163.19588,"timestamp":1791417251369,"change":0.0201,"changeRate":0.023653,"amplitude":0.10579},"delay":0,"changeRate":-0.01983852364475201,"floatShares":1387907,"shares":2369700,"eps":-3.1005669,"marketStatus":"Not Yet Opened","change":-0.0172,"latestTime":"10-07 16:00:00 EDT","open":0.78,"high":0.9,"low":0.761,"amount":7908438.03978592,"amplitude":0.160323,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-3.1005669,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791446400000},"marketStatusCode":0,"adr":0,"listingDate":1776916800000,"exchange":"NASDAQ","adjPreClose":0.867,"preHourTrading":{"tag":"盘前","latestPrice":0.7835,"preClose":0.867,"latestTime":"09:28 EDT","volume":4416207,"amount":4190543.238507,"timestamp":1791379694805,"change":-0.0835,"changeRate":-0.096309,"amplitude":0.426298},"postHourTrading":{"tag":"盘后","latestPrice":0.8699,"preClose":0.8498,"latestTime":"19:54 EDT","volume":41373,"amount":35163.19588,"timestamp":1791417251369,"change":0.0201,"changeRate":0.023653,"amplitude":0.10579},"volumeRatio":37.8779},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABT\",,,,,undefined,":{"symbol":"LABT","floatShares":1387907,"roa":"-139.40%","roe":"-402.84%","lyrEps":-8.39872,"volumeRatio":37.8779,"shares":2369700,"dividePrice":0,"high":0.9,"amplitude":0.160323,"preClose":0.867,"low":0.761,"week52Low":0.761,"pbRate":"0.46","week52High":98.2,"institutionHeld":0,"latestPrice":0.8498,"eps":-3.1005669,"divideRate":0,"volume":8498672,"delay":0,"ttmEps":-3.1005669,"open":0.78,"prevYearClose":80,"prevWeekClose":0.9326,"prevMonthClose":0.9553,"prevQuarterClose":0.9553,"fiveDayClose":0.9553,"twentyDayClose":2.32,"sixtyDayClose":2.55},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-06-22","symbol":"LABT","defaultRemindTime":1782135000000,"type":"split","dateTimestamp":1782100800000,"forFactor":10,"toFactor":1,"ratio":10}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABT\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LABT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LABT","date":"2026-10-06","current":-0.274079,"percent":1,"low":-12.282138,"twenty":-2.649964,"median":-0.83425,"eighty":-0.66762,"high":-0.275724,"avg":-2.112368,"sd":2.952329,"marketCap":2025846},"quantilePoints":[{"date":"2026-05-08","current":-12.282138,"twenty":-12.192813,"median":-11.891342,"eighty":-11.604759,"marketCap":47257207},{"date":"2026-05-15","current":-7.294845,"twenty":-12.043939,"median":-11.649421,"eighty":-11.314454,"marketCap":28067917},{"date":"2026-05-22","current":-2.865088,"twenty":-11.850402,"median":-11.258627,"eighty":-3.412052,"marketCap":11023817},{"date":"2026-05-29","current":-2.716586,"twenty":-11.716415,"median":-6.438817,"eighty":-2.758568,"marketCap":10452435},{"date":"2026-06-05","current":-2.512255,"twenty":-11.604759,"median":-3.225364,"eighty":-2.559299,"marketCap":9666247},{"date":"2026-06-12","current":-2.69016,"twenty":-11.537766,"median":-2.813168,"eighty":-2.512255,"marketCap":10350760},{"date":"2026-06-18","current":-2.241304,"twenty":-11.42611,"median":-2.776507,"eighty":-2.512255,"marketCap":8623724},{"date":"2026-06-26","current":-1.276597,"twenty":-10.242559,"median":-2.72924,"eighty":-2.388094,"marketCap":4911883},{"date":"2026-07-02","current":-1.116845,"twenty":-7.294845,"median":-2.69016,"eighty":-1.477578,"marketCap":4725718},{"date":"2026-07-10","current":-0.893476,"twenty":-5.58279,"median":-2.580737,"eighty":-1.276597,"marketCap":3780575},{"date":"2026-07-17","current":-0.62611,"twenty":-3.536511,"median":-2.512255,"eighty":-1.062695,"marketCap":2649266},{"date":"2026-07-24","current":-1.03562,"twenty":-3.225364,"median":-2.41344,"eighty":-0.92732,"marketCap":4382030},{"date":"2026-07-31","current":-0.653185,"twenty":-2.937143,"median":-2.34533,"eighty":-0.879262,"marketCap":2763829},{"date":"2026-08-07","current":-0.754716,"twenty":-2.857942,"median":-1.477578,"eighty":-0.80819,"marketCap":3193440},{"date":"2026-08-14","current":-0.78856,"twenty":-2.830251,"median":-1.371504,"eighty":-0.793975,"marketCap":3336643},{"date":"2026-08-21","current":-0.706322,"twenty":-2.806803,"median":-1.276597,"eighty":-0.779084,"marketCap":5189616},{"date":"2026-08-28","current":-0.803079,"twenty":-2.760875,"median":-1.18284,"eighty":-0.754039,"marketCap":5900523},{"date":"2026-09-04","current":-0.612791,"twenty":-2.735567,"median":-1.116845,"eighty":-0.749426,"marketCap":4502407},{"date":"2026-09-11","current":-0.661169,"twenty":-2.730282,"median":-1.03562,"eighty":-0.735555,"marketCap":4857860},{"date":"2026-09-18","current":-0.59989,"twenty":-2.721648,"median":-0.925628,"eighty":-0.713886,"marketCap":4407619},{"date":"2026-09-25","current":-0.588602,"twenty":-2.70073,"median":-0.89016,"eighty":-0.694712,"marketCap":4324680},{"date":"2026-10-02","current":-0.299977,"twenty":-2.666042,"median":-0.854556,"eighty":-0.672485,"marketCap":2204046},{"date":"2026-10-06","current":-0.275724,"twenty":-2.649964,"median":-0.83425,"eighty":-0.66762,"marketCap":2025846}],"updateTime":1791435500757},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABT\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673090265","title":"Lakewood-Amedex Says Lead Bisphosphocin Candidate Nu-3 Posts Phase 2a Diabetic Foot Ulcer Trial Data in Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2673090265","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673090265?lang=en_us&edition=fundamental","pubTime":"2026-10-07 20:02","pubTimestamp":1791374562,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex says lead Bisphosphocin candidate Nu-3 posts Phase 2a diabetic foot ulcer trial data in Q1 2027Lakewood-Amedex Biotherapeutics reported positive preclinical results for Bisphosphocin c","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nNDL1rsVLY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673902310","title":"Lakewood-Amedex Biotherapeutics - Bisphosphocin Nu-3 Phase 2a Trial Topline Data Expected Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2673902310","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673902310?lang=en_us&edition=fundamental","pubTime":"2026-10-07 20:02","pubTimestamp":1791374545,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nFWN45T111:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673287090","title":"Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds","url":"https://stock-news.laohu8.com/highlight/detail?id=2673287090","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673287090?lang=en_us&edition=fundamental","pubTime":"2026-10-07 20:02","pubTimestamp":1791374545,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nFWN45T111:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672724754","title":"Lakewood-Amedex CEO Presents Nu-3 Preclinical Poster at IDWeek","url":"https://stock-news.laohu8.com/highlight/detail?id=2672724754","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672724754?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:04","pubTimestamp":1790856262,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex CEO presents Nu-3 preclinical poster at IDWeekLakewood-Amedex will attend the Maxim Growth Summit on Oct. 13-14, 2026 in New York City.CEO Kelvin Cooper will present at the ThinkEquity","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDLHfmcJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671729218","title":"Lakewood-Amedex Biotherapeutics Holds Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2671729218","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671729218?lang=en_us&edition=fundamental","pubTime":"2026-09-29 18:01","pubTimestamp":1790676108,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics holds annual shareholder meetingLakewood-Amedex Biotherapeutics held its annual shareholder meeting on Sept. 22, 2026.Shareholders backed an articles amendment raising ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nNDL20d8hV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670538152","title":"Why Is Penny Stock Lakewood-Amedex Biotherapeutics (LABT) Up 20% Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2670538152","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670538152?lang=en_us&edition=fundamental","pubTime":"2026-09-28 21:47","pubTimestamp":1790603250,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics stock rallied on Monday after it announced new data for its lead candidate.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/why-is-penny-stock-lakewood-amedex-biotherapeutics-labt-up-20-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/why-is-penny-stock-lakewood-amedex-biotherapeutics-labt-up-20-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670232718","title":"Lakewood-Amedex Biotherapeutics reports positive MIC data from Nu-3 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2670232718","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670232718?lang=en_us&edition=fundamental","pubTime":"2026-09-28 20:11","pubTimestamp":1790597462,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics (LABT) announced positive Minimum Inhibitory Concentration data from recent clinical isolates for its lead clinical...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lakewood-amedex-biotherapeutics-reports-positive-mic-data-from-nu-3-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lakewood-amedex-biotherapeutics-reports-positive-mic-data-from-nu-3-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670643232","title":"Lakewood-Amedex Reports Positive MIC Data for Nu-3 Against Infected Diabetic Foot Ulcer Isolates","url":"https://stock-news.laohu8.com/highlight/detail?id=2670643232","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670643232?lang=en_us&edition=fundamental","pubTime":"2026-09-28 20:05","pubTimestamp":1790597135,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex reports positive MIC data for Nu-3 against infected diabetic foot ulcer isolatesLakewood-Amedex Biotherapeutics reported positive lab data for Nu-3 against recent bacterial samples fro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nNDLbsZ7gm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670346232","title":"Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers","url":"https://stock-news.laohu8.com/highlight/detail?id=2670346232","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670346232?lang=en_us&edition=fundamental","pubTime":"2026-09-28 20:02","pubTimestamp":1790596943,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nFWN45K0BS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669046065","title":"Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers","url":"https://stock-news.laohu8.com/highlight/detail?id=2669046065","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669046065?lang=en_us&edition=fundamental","pubTime":"2026-09-24 20:02","pubTimestamp":1790251320,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nTUA4B3QWS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669816365","title":"Lakewood-Amedex Biotherapeutics Lists on NASDAQ Capital Market Under LABT Ticker","url":"https://stock-news.laohu8.com/highlight/detail?id=2669816365","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669816365?lang=en_us&edition=fundamental","pubTime":"2026-09-21 20:04","pubTimestamp":1789992286,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics lists on Nasdaq Capital Market under LABT tickerLakewood-Amedex Biotherapeutics shifted its stock listing to the Nasdaq Capital Market under ticker LABT on April 23, 20","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nNDL2LLlTl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668751499","title":"Lakewood-Amedex Biotherapeutics - Prospectus Filed for Resale of up to 4,512,400 Shares of Common Stock by Certain Selling Stockholder - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2668751499","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668751499?lang=en_us&edition=fundamental","pubTime":"2026-09-19 05:32","pubTimestamp":1789767168,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nFWN45A0KA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668923218","title":"Lakewood-Amedex Biotherapeutics Announces Irb Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers","url":"https://stock-news.laohu8.com/highlight/detail?id=2668923218","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668923218?lang=en_us&edition=fundamental","pubTime":"2026-09-18 20:14","pubTimestamp":1789733645,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nTUABR3JPG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320968","title":"Lakewood-Amedex Biotherapeutics CEO Presents at H.C. Wainwright Global Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320968","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320968?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:07","pubTimestamp":1788869252,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics CEO presents at H.C. Wainwright Global Investment ConferenceLakewood-Amedex Biotherapeutics will present virtually at the H.C. Wainwright 28th Annual Global Investment ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDLb7XN0v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659110010","title":"Lakewood-Amedex Q2 FY26 Net Loss Widens to $3.77 Million; R&D Expense More than Doubled to $503,020","url":"https://stock-news.laohu8.com/highlight/detail?id=2659110010","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659110010?lang=en_us&edition=fundamental","pubTime":"2026-08-14 18:08","pubTimestamp":1786702114,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Q2 FY26 net loss widens to $3.77 million; R&D expense more than doubled to $503,020Lakewood-Amedex posted a net loss of $3.77 million for the quarter ended June 30, 2026, widening from the prior-year period.Operating loss widened to $3.79 million as total operating expenses climbed to $3.79 million.Research and development spending more than doubled to $503,020, driven by higher manufacturing, regulatory and clinical planning for Nu-3 Phase 2a.General and administrative costs jumped to $3.29 million, mainly due to $2.4 million in noncash professional services tied to stock issuance.Series C Convertible Preferred Stock private placement raised about $6.8 million net; common stock began trading on Nasdaq Capital Market on April 23.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL2kZSYf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658954040","title":"Lakewood-Amedex Biotherapeutics Announces Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2658954040","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658954040?lang=en_us&edition=fundamental","pubTime":"2026-08-11 05:14","pubTimestamp":1786396498,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics announces annual shareholder meetingLakewood-Amedex Biotherapeutics will hold its annual shareholder meeting virtually on Sept. 22, 2026.Shareholders will vote to elect","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDL8pvPMK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655939386","title":"Lakewood-Amedex Biotherapeutics Announces Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2655939386","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655939386?lang=en_us&edition=fundamental","pubTime":"2026-07-31 04:33","pubTimestamp":1785443614,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics announces annual shareholder meetingLakewood-Amedex Biotherapeutics will hold its annual stockholder meeting virtually on September 22, 2026.Shareholders will vote on e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nNDL4nbJ9R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653577357","title":"Lakewood-amedex Biotherapeutics Flags New Press Release Available on Nu-3 Resistance Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2653577357","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653577357?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:04","pubTimestamp":1784721865,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics flags new press release available on Nu-3 resistance dataLakewood-Amedex published a July 22, 2026 release highlighting new resistance data for Nu-3, its Phase 2-ready ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nNDL5F7T3W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651946871","title":"Lakewood-Amedex announces preclinical data from Phase 2a clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2651946871","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651946871?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:10","pubTimestamp":1784117436,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics (LABT) announced robust preclinical safety data that establishes a strong foundation for clinical dose selection in...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lakewood-amedex-announces-preclinical-data-from-phase-2a-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lakewood-amedex-announces-preclinical-data-from-phase-2a-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","HYLG","LABT","GDOC","MEDX","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651446850","title":"Lakewood-amedex Biotherapeutics Reports Release Available on Nu-3 Gel Preclinical Safety Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2651446850","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651446850?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:05","pubTimestamp":1784117146,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics reports release available on Nu-3 gel preclinical safety dataLakewood-Amedex Biotherapeutics posted preclinical safety data supporting dose selection for a planned Phas","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDL2m8FqM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":50,"code":"91000000","status":"200"}]}}